Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients.

Notably, those who received nivolumab exhibited higher rates of hepatitis B surface antigen (HBsAg) loss compared to other groups. This is seen as a significant step forward in targeting HBsAg ...

Interim results from the phase 2b B-Clear showed that bepirovirsen reduced levels of hepatitis B surface antigen (HBsAg) and HBV DNA after 24 weeks' treatment to below the lower limit of detection ...

Hepatitis B surface antigen vaccine (recombinant) 5mcg/0.5mL; susp for IM inj; aluminum hydroxide adsorbed; preservative-free. Ped/Adolescent 5mcg/0.5mL: single-dose vials (yellow cap), single ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

Brelovitug (BJT-778) is a fully human immunoglobulin G1 monoclonal antibody designed to target hepatitis B surface antigen and neutralize and remove HBV and HDV virions. The company reports that ...

Alliance Global Partners analyst James Molloy lowered the firm’s price target on Barinthus Biotherapeutics (BRNS) to $6 from $7.50 and keeps a ...

The report highlighted that testing was conducted for the presence of Hepatitis B surface antigen (HBsAg) and antibodies to Hepatitis C virus (anti-HCV) as biomarkers for Hepatitis B and Hepatitis ...

bepirovirsen at a dose of 300 mg per week over 24 weeks resulted in sustained hepatitis B surface antigen (HBsAg) and HBV DNA loss to below the limits of detection in 9% to 10% of participants ...

Discover a clinical trial that was conducted to evaluate the efficacy and safety of autologous HBV vaccine-pulsed dendritic cells and their induced T cells.

Existing treatment criteria for chronic hepatitis B virus (HBV) infection are mainly based on data from observational studies, such as the REVEAL study from Taiwan, which was initiated in the early ...

Thirty-four HBsAg tests were performed on 34 different patients within 14 days of a dose of Engerix-B® hepatitis B vaccine, with 24 of these occurrences involving patients with chronic renal ...